U.S., Aug. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07773454) titled 'Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid Tumors' on Aug. 12.
Brief Summary: The primary purpose of this study is to determine the pediatric maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), and to evaluate the safety and tolerability of zanzalintinib.
Study Start Date: Sept. 30
Study Type: INTERVENTIONAL
Condition:
Cancer
Pediatric Cancer
Intervention:
DRUG: Zanzalintinib
Administered as specified in the treatment arm.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Exelixis
Published by HT Digital Content Services with permission from Health Daily Digest....